Clinical Trial Update: Iparomlimab and Tuvonralimab (QL1706) for Intermediate Trophoblastic Tumors [Phase 1, Phase 2]

View source ↗

Summary

This document reports a Phase 1/2 clinical trial evaluating Iparomlimab and Tuvonralimab (QL1706) for intermediate trophoblastic tumors, with recruitment ongoin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intermediate Trophoblastic Tumor

Drugs mentioned

• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Intermediate Trophoblastic Tumor | Phase 1, Phase 2 | Status: RECRUITING